AllSci News
Biond Biologics secures USD 8m from GIBF for China oncology JV
Biond Biologics, a private clinical-stage biotechnology company based in Misgav, Israel, and the Guangzhou-Israel Biotechnology Fund (GIBF) announced the closing of an…
Wockhardt antibiotic becomes first fully India-discovered NCE to win US approval
Wockhardt wins FDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic targeting drug-resistant Gram-negative bacteria in adults with complicated urinary…
FDA approves Haisco’s Cypsedo for intravenous anesthesia induction in adults
The US FDA has approved Cypsedo (cipepofol, formerly ciprofol/HSK 3486) injection, an intravenous anesthetic developed by China’s Haisco Pharmaceutical Group, marking the…
Eli Lilly expands Camurus FluidCrystal collaboration to amylin receptor agonists, USD 870m deal
Eli Lilly (NYSE: LLY) has expanded its collaboration with Camurus (Nasdaq Stockholm: CAMX) to include amylin receptor agonists, exercising a pre-negotiated...
MannKind’s Afrezza inhaled insulin wins FDA pediatric label expansion nod
MannKind Corporation announced that the US FDA has approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6…
SK Bio secures USD 230m in government financing for Sanofi-partnered pneumococcal vaccine
SK bioscience, the Songdo, Incheon-based vaccine and biotech company, has secured KRW 300 billion (approximately USD 230 million) in long-term, low-interest...
Nouscom’s NOUS-209 viral vector neoantigen vaccine earns FDA Fast Track for Lynch Syndrome cancer prevention
Nouscom, a clinical-stage biotech headquartered in Basel, Switzerland, announced receipt of US FDA Fast Track Designation for NOUS-209, a viral vector-based, off-the-shelf…
Oculis' lead candidate fails to meet primary endpoint in Phase III diabetic macular edema trials
Oculis Holding AG (Nasdaq: OCS) reported that OCS-01, its topical eye drop formulation under investigation for diabetic macular edema, failed to meet the...
Bristol Myers Squibb’s mavacamten gains FDA Priority Review for adolescent oHCM
Bristol Myers Squibb (NYSE: BMY), headquartered in Princeton, New Jersey, announced receipt of US FDA Priority Review for a supplemental New Drug…
Servier acquires Edgewise muscular dystrophy business for USD 2.65b including sevasemten rights
France-based Servier will acquire sevasemten and Edgewise Therapeutics' muscular dystrophy business for USD 1.55 billion in upfront cash plus up to USD 1.1...
ASCO: Revolution Med posts full Phase III pancreatic cancer data set for daraxonrasib
Revolution Medicines (Nasdaq: RVMD) reported Phase III data showing that daraxonrasib, an oral RAS(ON) multi-selective inhibitor, cut the risk of death by...
Oak Hill Bio raises USD 32.5m Series A to advance rugonersen toward pivotal Angelman trial
Cambridge, Massachusetts-based Oak Hill Bio, a clinical-stage rare disease company focused on repurposing deprioritized pharma assets, has closed a USD 32.5...
Curium commits EUR 32m strategic investment to Saclay radiopharmaceuticals facility
Curium, the Paris-headquartered radiopharmaceutical company, has announced a strategic capital investment exceeding EUR 32 million at its Saclay, France...
Lilly licenses Hanmi's GLP-2 agonist sonefpeglutide in USD 1.26b deal
Eli Lilly (NYSE: LLY) has agreed to pay USD 75 million upfront to license sonefpeglutide, a long-acting GLP-2 receptor agonist biologic, from South Korean...
Agios bags license to Oscotec's SYK inhibitor cevidoplenib in USD 165m deal
Agios Pharmaceuticals (Nasdaq: AGIO) has licensed exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor developed by South Korean...
The AllSci Brief
Systematic R&D and deal news. Daily.